Association between SHBG (TAAAA)n and AR (CAG)n polymorphisms and PCOS risk: A meta-analysis

Figure 1 Strategy for searching studies concerning the association between the (TAAAA)n sex hormone-binding globulin polymorphism and polycystic ovarian syndrome risk. PCOS: Polycystic ovarian syndrome.

Figure 2 Strategy for searching studies concerning the association between the (CAG)n androgen receptor polymorphisms and polycystic ovarian syndrome risk. AR: Androgen receptor; PCOS: Polycystic ovarian syndrome.

Figure 3 Association between polycystic ovarian syndrome risk and (TAAAA)n sex hormone-binding globulin alleles. A: Comparison of short alleles in the PCOS group with those in the control group; B: Comparison of long alleles in the PCOS group with those in the control group. PCOS: Polycystic ovarian syndrome.

Figure 4 Association between polycystic ovarian syndrome risk and (TAAAA)n sex hormone-binding globulin genotypes. A-C: Comparison of short-short (A), short-long (B), long-long (C) genotype in the PCOS group with those in the control group. PCOS: Polycystic ovarian syndrome.

Figure 5 Association between polycystic ovarian syndrome risk and (CAG)n repeats in androgen receptor in all selected studies. WMD: Weighted mean difference.

Figure 6 Association between polycystic ovarian syndrome risk and (CAG)n repeats in polycystic ovarian syndrome by race. A: Asian; B: Caucasian. WMD: Weighted mean difference.

Figure 7 Association between polycystic ovarian syndrome diagnosed according to the criteria of Rotterdam Revised 2003 and (CAG)n repeats in androgen receptor. WMD: Weighted mean difference.